AFIDA-1

Atrial Fibrillation-Related Ischemic Stroke Despite Anticoagulation-1 Prospective Cohort Study (AFIDA-1) - AFIDA-1

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1050240284

Enrollment

520

Registered

2025-03-05

Start date

2025-05-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic stroke, transient ischemic attack, non-valvular atrial fibrillation Ischemic stroke, transient ischemic attack, non-valvular atrial fibrillation

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients with ischemic stroke or transient ische Inclusion Criteria mic attack (TIA) within 28 days of onset 2) Patients with NVAF who receive oral anticoagulation at the time of onset 3) Patients 18 years or older at the time of informed consent 4) Patients for whom written informed consent has been obtained from the person or proxy

Exclusion criteria

Exclusion criteria: 1) Patients after mechanical valve replacement 2) Patients with severe mitral stenosis 3) Patients who have already participated or will participate in other clinical trials 4) Patients deemed by the physician to be unsuitable to participate in the study.

Design outcomes

Primary

Measure	Time frame
Incidence of the composite outcome of recurrent ischemic stroke /systemic embolism within 48 weeks of enrollment	—

Secondary

Measure	Time frame
1) Incidence of composite outcome of stroke and systemic embolism within 48 weeks of enrollment 2) Incidence of stroke within 48 weeks of enrollment 3) Incidence of disabling stroke (increased modified Rankin Scale [mRS]>=2) within 48 weeks of enrolment 4) Incidence of recurrent ischemic stroke within 48 weeks of enrollment 5) Incidence of recurrent disabling ischemic stroke (change in mRS>=2) within 48 weeks of enrollment 6) Incidence of systemic embolism within 48 weeks of enrollment 7) Incidence of cardiovascular death within 48 weeks of enrollment 8) Incidence of unexplained death within 48 weeks of enrollment 9) Incidence of cardiovascular death or unexplained death within 48 weeks of enrollment 10) Incidence of major bleeding within 48 weeks of enrollment 11) Incidence of intracranial hemorrhage within 48 weeks of enrolment 12) Incidence of major extracranial bleeding within 48 weeks of enrolment 13) Incidence of all-cause death within 48 weeks of enrolment	—

Measure

Time frame

1) Incidence of composite outcome of stroke and systemic embolism within 48 weeks of enrollment 2) Incidence of stroke within 48 weeks of enrollment 3) Incidence of disabling stroke (increased modified Rankin Scale [mRS]>=2) within 48 weeks of enrolment 4) Incidence of recurrent ischemic stroke within 48 weeks of enrollment 5) Incidence of recurrent disabling ischemic stroke (change in mRS>=2) within 48 weeks of enrollment 6) Incidence of systemic embolism within 48 weeks of enrollment 7) Incidence of cardiovascular death within 48 weeks of enrollment 8) Incidence of unexplained death within 48 weeks of enrollment 9) Incidence of cardiovascular death or unexplained death within 48 weeks of enrollment 10) Incidence of major bleeding within 48 weeks of enrollment 11) Incidence of intracranial hemorrhage within 48 weeks of enrolment 12) Incidence of major extracranial bleeding within 48 weeks of enrolment 13) Incidence of all-cause death within 48 weeks of enrolment

—

Contacts

Public Contactkanta tanaka

Kindai University Hospital

tanaka19830311kanta@gmail.com+81-72-288-7222

Outcome results